Izotropic Corp. · CSE:IZO
Izotropic — Investor Presentation (March 2024)
13 slides from Izotropic's investor presentation, March 2024
Slide 1: Investor Presentation
INVESTOR PRESENTATION For illustrative purposes only. IzoView is not yet approved for sale CSE: IZO OTCQB: IZOZF IZOVIEW IMAGING SYSTEM
Slide 2: Izotropic Overview
IZOTROPIC OVERVIEW The only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. BREAST CT EVOLUTION GROWING MARKET REGULATORY $20M spent on R&D to date via Breast imaging market growing from Patient
Slide 3: 5th Generation Device
5TH GENERATION DEVICE First device for commercialization Proof of Concept Units by Dr. John M. Boone at UC Davis Four successive laboratory prototypes Over 600 patients imaged in a clinical study validating the technology Second ongoing clinical study with 400 patients underway IzoView for Commercia
Slide 4: Licensed Technology & Intellectual Property
LICENSED TECHNOLOGY & INTELLECTUAL PROPERTY GLOBAL LICENSING RIGHTS Exclusive worldwide licensing rights to Breast CT through an agreement with The Regents of The University of California Developed over 20 years by principal technology founder and company director Dr. John M. Boone Commercialization
Slide 5: Breast Cancer Is Now the Most Common Form of the Disease
BREAST CANCER IS NOW THE MOST COMMON FORM OF THE DISEASE U.S. Breast Cancer Landscape Facts. 41M BREASTS SCANS IN 2019 280K NEW BREAST CANCER CASES / YEAR Screening mammography misses 1/ 5 cancers 1 in 8 women will be diagnosed with breast >8,500 MSQA Certified imaging centers and cancer in their li
Slide 6: Diagnostic Mammography Challenges
DIAGNOSTIC MAMMOGRAPHY CHALLENGES Limitations of the current standard of care. CONTINUAL BREAST COMPRESSION Technician manipulation of the breast for multiple imaging views 46% of patient non-compliance is due to pain Concerns with breast implants (ie. discomfort and rupture) REQUIRES TECHNICAL SKIL
Slide 7: IzoView Breast CT
IZOVIEW BREAST CT A whole new experience for patients, radiologists and providers. NO BREAST COMPRESSION Natural breast orientation preserved, no pain or discomfort, very comfortable face down view, excellent visualization with contrast PATIENT EMPOWERMENT Patient places own breast in imaging cup, n
Slide 8: Solving an Unmet Need
SOLVING AN UNMET NEED Images below are of the same breast. Mammography Tomosynthesis 2D Image True 3D, 360 degree 1 single image slice 2.5D Image of the 500 obtained CSE: IZO OTCQB: IZOZF IZOVIEW IMAGING SYSTEM - 8
Slide 9: IzoView Platform Uses
IZOVIEW PLATFORM USES Making Breast CT an indispensable tool for improving the outcomes of breast cancer. STEPS TO SCREENING DIAGNOSTIC BIOPSY TREATMENT MONITORING TREATMENT: PLATFORM NEW INDICATIONS INITIAL REGULATORY NEW ACCESSORIES NEW DEVICES NEW SOFTWARE PRODUCTS: FOCUS SALES ONE TIME, RENTAL,
Slide 10: Broad Engagement Preparing for Market Entrance
BROAD ENGAGEMENT PREPARING FOR MARKET ENTRANCE Near-term catalysts across multiple workstreams. DEVELOPMENT REIMBURSEMENT REGULATORY AI software modules and hardware Expanding payor engagement Discussions with jurisdictions outside accessories to expand IzoView Collaborating with payors on of U.S. p
Slide 11: Directors & Management
DIRECTORS & MANAGEMENT BOB THAST JOHN M. BOONE, PHD YOUNES ACHKIRE, PHD ANDREW HERNANDEZ, PHD Interim CEO, Director Founder & Director Chief Operating Officer Head of Imaging Technology Capital markets specialist, Medical Physicist, Professor, Medical device R&D expert, managing Biomedical Engineer,
Slide 12: Medical & Scientific Advisors
MEDICAL & SCIENTIFIC ADVISORS Internationally Recognized Specialists that played vital roles in establishing current standards of breast care. DR. MARTIN YAFFE, PHD CRAIG SHIMASAKI, PHD, MBA DR. JEFF SIEWERDSEN, PHD University of Toronto, SunnyBrook Hospital Northwestern Johns Hopkins University Dro
Slide 13: Disclaimer
DISCLAIMER This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates.